Carderock Capital Management Inc. Buys 5,662 Shares of Thermo Fisher Scientific Inc. $TMO

Carderock Capital Management Inc. lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 36.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,017 shares of the medical research company’s stock after purchasing an additional 5,662 shares during the quarter. Thermo Fisher Scientific comprises approximately 3.0% of Carderock Capital Management Inc.’s portfolio, making the stock its 8th biggest position. Carderock Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $12,178,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. JPL Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the third quarter worth about $28,000. Highline Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after buying an additional 33 shares in the last quarter. Capital A Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 825.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 66 shares during the period. Cloud Capital Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $31,000. Finally, Howard Hughes Medical Institute purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $33,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on TMO. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 target price on the stock in a research report on Sunday, December 7th. Citigroup lifted their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, Evercore reaffirmed an “outperform” rating and issued a $650.00 price target on shares of Thermo Fisher Scientific in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $633.68.

Thermo Fisher Scientific Stock Up 0.8%

Shares of NYSE TMO opened at $478.29 on Tuesday. The firm has a market cap of $177.67 billion, a P/E ratio of 26.96, a price-to-earnings-growth ratio of 2.74 and a beta of 0.96. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The firm’s 50 day moving average price is $540.67 and its 200 day moving average price is $548.27.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The company had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same period in the previous year, the firm posted $6.10 EPS. Thermo Fisher Scientific’s revenue was up 7.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date is Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.60%.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares of the company’s stock, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.